Can cefixime be used to treat uncomplicated typhoid fever, and what are the appropriate adult and pediatric dosing regimens?

Can Cefixime Be Used for Uncomplicated Typhoid Fever?

Cefixime can be used as an alternative oral agent for uncomplicated typhoid fever, but it is inferior to azithromycin and carries documented treatment failure rates of 4-37.6%, requiring mandatory test-of-cure at 1 week. 1, 2

First-Line Treatment Recommendation

• Azithromycin is the preferred first-line therapy for uncomplicated typhoid fever, particularly in regions with high fluoroquinolone resistance (>70% in South Asia). 1, 2
• Azithromycin reduces clinical failure by 52% compared to fluoroquinolones (OR 0.48,95% CI 0.26-0.89) and shortens hospital stays by approximately 1 day. 1, 2
• Relapse risk with azithromycin is 91% lower than ceftriaxone (OR 0.09,95% CI 0.01-0.70). 1, 2

Dosing for Azithromycin

• Adults: 500 mg orally once daily for 7 days 1, 2
• Children: 20 mg/kg/day orally once daily (maximum 1 g/day) for 7 days 1, 2

When Cefixime May Be Considered

Cefixime should only be used when azithromycin and ceftriaxone are unavailable or contraindicated, and only with the following critical caveats:

Dosing for Cefixime

• Adults: 400 mg orally once daily for 7 days 3
• Children: 20 mg/kg/day orally in two divided doses (maximum 400 mg twice daily) for 7 days 4

Documented Limitations of Cefixime

• Treatment failure rates range from 4% to 37.6% in clinical practice. 1, 2
• Cefixime carries a 13-fold higher risk of clinical failure compared to fluoroquinolones (RR 13.39,95% CI 3.24-55.39). 2
• In a head-to-head trial with ofloxacin in Vietnamese children, cefixime showed significantly more treatment failures and longer duration of fever, poor eating, and immobility. 3
• The World Health Organization lists cefixime only as an "alternative" option, not first-line therapy. 1, 2

Mandatory Follow-Up

• If cefixime is used, a test-of-cure at 1 week is required due to high failure rates. 3, 1

Alternative Second-Line Therapy

Ceftriaxone is superior to cefixime when parenteral therapy is acceptable:

• Adults: 1-2 g IV/IM once daily for 5-7 days 1, 5
• Children: 50-75 mg/kg IV/IM once daily (maximum 2 g) for 5-7 days 1, 5
• Ceftriaxone achieves clinical cure rates of 79-83% and maintains efficacy against multidrug-resistant strains. 5
• However, azithromycin still demonstrates lower relapse rates than ceftriaxone. 1, 2

Critical Pitfalls to Avoid

• Do not use fluoroquinolones empirically for cases from South or Southeast Asia, where resistance exceeds 70-96%. 1, 2
• Do not use cefuroxime (a second-generation cephalosporin) when third-generation agents are available, as it has significantly weaker activity against Salmonella species. 1
• Complete the full 7-day course even if fever resolves early; premature discontinuation increases relapse risk to 10-15%. 1, 2
• Obtain blood cultures before starting antibiotics whenever possible, as they have the highest diagnostic yield (40-80% sensitivity) in the first week. 1, 2

Expected Clinical Response

• Fever should resolve within 4-5 days of appropriate therapy. 1, 2, 5
• Lack of improvement by day 5 warrants evaluation for antimicrobial resistance or alternative diagnosis. 1, 2
• With azithromycin, mean fever clearance time is 5.8 days (95% CI 5.1-6.5 days). 2, 6

Geographic Resistance Considerations

• Over 70% of S. Typhi isolates from South Asia are fluoroquinolone-resistant. 1, 2
• In Thailand, 93% of isolates are ciprofloxacin-resistant. 1, 2
• All S. Typhi isolates remain susceptible to third-generation cephalosporins (ceftriaxone, cefixime), though cefixime has higher clinical failure rates. 2

Pregnancy Considerations

• Azithromycin is FDA Pregnancy Category B and may be used safely in pregnant patients. 2
• Fluoroquinolones are contraindicated in pregnancy. 2
• Ceftriaxone is also safe in pregnancy when parenteral therapy is needed. 5